...
首页> 外文期刊>Taiwanese journal of obstetrics and gynecology >Effects of silymarin, cabergoline and letrozole on rat model of endometriosis
【24h】

Effects of silymarin, cabergoline and letrozole on rat model of endometriosis

机译:水飞蓟素,卡麦角林和来曲唑对子宫内膜异位症大鼠模型的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

ObjectiveSilymarin as an herbal drug has potent antioxidant effects that could make it a good choice for endometriosis therapy. The aim of the current study was to determine the effects of silymarin as an herbal drug on induced endometrial lesion in rat model of endometriosis.Materials and methodsA total of 32 mature, female Sprague–Dawley rats were allocated into 4 experimental groups. The duration of study was about 6 months. Endometriosis implants were surgically prepared and autografted into 32 rats. Three weeks after endometriosis induction, animals were randomly allocated into four groups: Group 1 received cabergoline (CAB group); Group 2 received letrozole (LET group); Group 3 received silymarin (SIL group) and Group 4 received no medication (CONT group). Experimental groups were treated for 3 weeks and then were sacrificed for volume and histopathological evaluation of implants and biochemical assessment. Serum and peritoneal levels of vascular endothelial growth factor (VEGF), total antioxidant activity (TAC) and tumor necrosis (TNF)-α were measured.ResultsMean volume of the implants decreased significantly in silymarin (p?
机译:目的水飞蓟素作为草药具有强大的抗氧化作用,使其成为子宫内膜异位症治疗的理想选择。本研究的目的是确定水飞蓟素作为草药在子宫内膜异位症模型中诱导的子宫内膜病变的作用。材料与方法将32只成年雌性Sprague-Dawley大鼠分为4个实验组。研究时间约为6个月。子宫内膜异位植入物经过外科手术准备,并自体移植到32只大鼠中。子宫内膜异位症诱导后三周,将动物随机分为四组:第1组接受卡麦角林(CAB组);第2组接受来曲唑(LET组);第3组接受水飞蓟素治疗(SIL组),第4组不接受药物治疗(CONT组)。实验组治疗3周,然后处死,进行体积和植入物的组织病理学评估以及生化评估。测定了血清和腹膜中血管内皮生长因子(VEGF),总抗氧化活性(TAC)和肿瘤坏死(TNF)-α的结果。水飞蓟素(p 0.001),来曲唑(p与对照组相比,α<< 0.001)和卡麦角林(p << 0.001)组。与对照组相比,水飞蓟素(p:0.039),来曲唑(p:0.017)和卡麦角林(p 0.001)组的组织病理学评分显着降低。接受水飞蓟素治疗的患者在治疗21天后的血清TAC较对照组显着更高(p 0.001)。结论水飞蓟素,来曲唑和卡麦角林的使用导致大鼠模型中子宫内膜病变的大小和组织病理学分级降低。水飞蓟素似乎是治疗子宫内膜异位症的虚拟新型治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号